-+ 0.00%
-+ 0.00%
-+ 0.00%

Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA

PUBT·09/30/2026 12:06:59
Listen to the news
Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA
  • Pierre Fabre Pharmaceuticals resubmitted the tabelecleucel BLA to the FDA for relapsed/refractory EBV+ PTLD in SOT or HCT patients.
  • Atara Biotherapeutics expects to provide a revised PDUFA date once the FDA sets the review timeline.
  • FDA approval would trigger a USD 31 million milestone payment to Atara under its Pierre Fabre commercialization deal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930946884) on September 30, 2026, and is solely responsible for the information contained therein.